Cannabis & Chronic Pain: What the Clinical Research Shows
States with medical cannabis laws show real differences in opioid mortality. What 30+ clinical trials say about cannabis for chronic pain management.
Evidence-based reporting on cannabis pharmacology, clinical trials, and peer-reviewed studies. Sourced from JAMA, NEJM, Nature, and leading research institutions worldwide.
States with medical cannabis laws show real differences in opioid mortality. What 30+ clinical trials say about cannabis for chronic pain management.
VA-backed clinical trials and patient surveys have produced some of the most compelling evidence for cannabis in mental health — specifically PTSD.
The clinical trials that led the FDA to approve Epidiolex in 2018 — and what they mean for other neurological conditions.
Every mammal has an endocannabinoid system. Understanding it is the key to understanding why cannabis has such wide-ranging effects on the body and mind.
Nabiximols (Sativex) is approved in 29 countries for MS spasticity. Here's the clinical trial evidence behind that approval and what it means.
CBD has shown meaningful anxiolytic effects in controlled trials. THC's relationship with anxiety is more complex — and dose-dependent.
From FDA-approved dronabinol to whole-plant cannabis — four decades of evidence for cannabis in managing cancer symptoms.
Cannabis consistently improves sleep onset and deep sleep in the short term. What happens with long-term use is more complicated.
CBD modulates multiple inflammatory pathways. Transdermal arthritis studies and cytokine research point toward real clinical potential.
Israeli clinical trials and observational studies show cannabis improves motor function and quality of life in Parkinson's patients.
Small but well-designed trials show cannabis reduces Crohn's disease activity — though the path to remission remains less clear.
From Mechoulam's 1964 discovery of THC to modern CB1 receptor mapping — the complete pharmacology of cannabis intoxication.
CBD works through at least a dozen molecular targets — none of them the CB1 receptor. Here's the complete mechanism science.
A landmark JAMA Internal Medicine study found 24.8% lower opioid overdose mortality in states with medical cannabis laws.
The same endocannabinoid system that regulates mood can be disrupted by heavy cannabis use. The honest picture is complicated.
Beta-caryophyllene directly activates CB2 receptors — making it a dietary cannabinoid. The science behind cannabis terpenes.
WADA removed CBD from banned substances in 2018. What the evidence says about cannabis for athletic recovery and pain.
THC inhibits amyloid aggregation in the lab. But clinical evidence in Alzheimer's patients remains thin and the safety risks are real.
Cannabis has a biphasic dose-response curve — the dose that relieves anxiety and the dose that triggers it can be closer than expected.
Synthetic THC has been FDA-approved for chemotherapy nausea since 1985. Here's 40 years of clinical evidence in oncology and AIDS care.
Cannabis users show lower fasting insulin and smaller waist circumference in large population studies. What the metabolic research actually shows — and the caveats.
From dysmenorrhea to menopause symptom relief, cannabis research is catching up to what millions of women already report. Here's what the clinical evidence shows so far.
Israeli researchers published some of the first controlled data on CBD for ASD behavioral symptoms. What the preliminary evidence shows — and why caution is still warranted.
Cannabis use among adults 65+ has tripled since 2015. Researchers are racing to understand what that means for cognition, neurodegeneration, and quality of life.
Same plant, radically different pharmacology. A deep dive into how THC and CBD interact with the endocannabinoid system differently — and what that means clinically.
Cannabis does reduce intraocular pressure — but only for 3–4 hours. Ophthalmology researchers explain why that makes it a poor fit for glaucoma management as currently understood.
Sub-perceptual THC doses are being studied for anxiety, focus, and mood. Separating the hype from what peer-reviewed research has actually documented so far.
CBD shows anti-inflammatory promise for cardiovascular disease while heavy THC use is linked to elevated heart rate and rare adverse events. A balanced look at the cardiac evidence.
About 9% of cannabis users develop dependence — lower than alcohol, tobacco, or opioids, but real. Clinical research on who is most at risk and what treatment evidence exists.
The fastest-growing cannabis demographic is adults over 60. Clinical research on dosing considerations, drug interactions, and efficacy for age-related conditions.
Every article in the TokeHead Research Center cites peer-reviewed studies published in indexed medical journals including JAMA, The New England Journal of Medicine, The Lancet, Nature, and PNAS. We link directly to PubMed or DOI for every citation so you can read the primary source yourself.
Our editorial team includes medical writers with backgrounds in pharmacology, neuroscience, and clinical medicine. Where evidence is strong, we say so clearly. Where it is limited, preliminary, or conflicting, we say that too. We do not promote cannabis as a cure for anything.
Every factual claim links to a primary source in a PubMed-indexed journal. No anonymous sources, no anecdote presented as evidence.
We report limitations and conflicting evidence alongside positive findings. Science that contradicts popular cannabis narratives gets covered honestly.
Research articles are for informational purposes only. Nothing here constitutes medical advice. Always consult a qualified healthcare provider.
Connect with growers, enthusiasts, and creators. Get 10 free Sparks just for signing up — no credit card required.